copied from stockhouse:
Stock price lost like 3x -20% the dilution 7%,
probably anticipating ongoing OS increase - of course, OS:
- 2016-03-31 58.47M
- 2016-12-31 81.66M
- 2017-03-31 87.93M
mcap
- 2016-03-31 $10.23M @ $0.175/sh - $14.62M @ $0.25/sh
- 2016-12-29 $24.49M @ $0.300/sh
- 2017-05-12 $20.66M @ $0.235/sh
Revenue is only about $1M per anno at a loss,
hence P/S 10 - 25 is given here, quite biggly.
A P/S 4 would lead to $4M mcap -> $0.045/sh only.
AFAIK company needs to hurry up big time to preserve the dream
of a big growth biotech - NOW.
Evaluations are surely overstretched at this point,
where our high expectations were disapointed.
JMO
Market Data 
Markets 
AI
